ADC Therapeutics SA (NYSE:ADCT)

$ 2.93 -0.05 (-1.68%) Market Cap: 283.30 Mil Enterprise Value: 112.41 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 46/100

Q2 2024 ADC Therapeutics SA Earnings Call Transcript
Aug 06, 2024

$2.92 (+1.74%)

Earnings
Q1 2024 ADC Therapeutics SA Earnings Call Transcript
May 06, 2024

$4.45 (-9.18%)

Earnings
Q4 2023 ADC Therapeutics SA Earnings Call Transcript
Mar 13, 2024

$3.9 (-12.36%)

Earnings
ADC Therapeutics SA at Jefferies London Healthcare Conference Transcript
Nov 14, 2023
Q3 2023 ADC Therapeutics SA Earnings Call Transcript
Nov 07, 2023

$0.7252 (-15.97%)

Earnings
ADC Therapeutics SA at Morgan Stanley Global Healthcare Conference Transcript
Sep 11, 2023
Q2 2023 ADC Therapeutics SA Earnings Call Transcript
Aug 08, 2023

$1.6 (+11.89%)

Earnings
ADC Therapeutics SA at RBC Capital Markets Global Healthcare Conference Transcript
May 16, 2023
Q1 2023 ADC Therapeutics SA Earnings Call Transcript
May 09, 2023

$2.17 (+2.36%)

Earnings
Full Year 2022 ADC Therapeutics SA Earnings Call Transcript
Feb 28, 2023

$3.6 (-11.55%)

Earnings
ADC Therapeutics SA at JPMorgan Healthcare Conference Transcript
Jan 11, 2023
Q3 2022 ADC Therapeutics SA Earnings Call Transcript
Nov 08, 2022

$4.14 (-2.82%)

Earnings
ADC Therapeutics SA at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2022
Q2 2022 ADC Therapeutics SA Earnings Call Transcript
Aug 09, 2022

$7.97 (-0.99%)

Earnings
Q1 2022 ADC Therapeutics SA Earnings Call Transcript
May 09, 2022

$7.81 (-28.68%)

Earnings
Q4 2021 ADC Therapeutics SA Earnings Call Transcript
Mar 03, 2022

$14.77 (-8.94%)

Earnings
ADC Therapeutics SA at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) Transcript
Feb 09, 2022
ADC Therapeutics SA To Discuss the highlighting of ADC Platform and Solid Tumor Pipeline Call Transcript
Feb 08, 2022
Q3 2021 ADC Therapeutics SA Earnings Call Transcript
Nov 02, 2021

$29.18 (-7.39%)

Earnings
ADC Therapeutics SA at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Sep 30, 2021
ADC Therapeutics SA at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 14, 2021
Q2 2021 ADC Therapeutics SA Earnings Call Transcript
Aug 03, 2021

$22.55 (+8.88%)

Earnings
ADC Therapeutics SA Presents At Bank of America Securities 2021 Healthcare Conference (Virtual) Transcript
May 11, 2021
Q1 2021 ADC Therapeutics SA Earnings Call Transcript
May 06, 2021

$22.61 (+2.77%)

Earnings
ADC Therapeutics SA Announces FDA Approval of ZYNLONTA™ - Conference Call Transcript
Apr 23, 2021
Q4 2020 ADC Therapeutics SA Earnings Call Transcript
Mar 18, 2021

$29.18 (-0.75%)

Earnings
ADC Therapeutics SA at Cowen Healthcare Conference (Virtual) Transcript
Mar 04, 2021
ADC Therapeutics SA Announces Updated Clinical Data on Lead Antibody Drug Conjugate Programs Loncastuximab Tesirine and Camidanlumab Tesirine Conference Call Transcript
Dec 07, 2020
Q3 2020 ADC Therapeutics SA Earnings Call Transcript
Nov 12, 2020

$33.96 (-2.05%)

Earnings
Q2 2020 ADC Therapeutics SA Earnings Call Transcript
Aug 18, 2020

$39 (+0.98%)

Earnings
ADC Therapeutics SA Call to Highlight Loncastuximab Tesirine (Lonca) Clinical Trial Data Transcript
Jun 12, 2020

Q3 2023 ADC Therapeutics SA Earnings Call Transcript

Nov 07, 2023 / 01:30PM GMT

Release Date Price: $0.7252 (-15.97%)

Transcript

Operator

Welcome to the ADC Therapeutics third-quarter 2023 financial results conference call. My name is Cathy, and I will be your operator for today's call. (Operator Instructions)

I'll now turn the call over to Eugenia Litz, Vice President of Investor Relations and Corporate Communications. Eugenia, you may now begin.

Eugenia Litz

ADC Therapeutics SA - VP, IR & Corporate Communications

Thank you, operator. This morning, we issued a press release announcing our third-quarter 2023 financial results and business update. This release is available on the ADCT website at ir.adctherapeutics.com under the Press Releases' section.

On today's call, Ameet Mallik, Chief Executive Officer; Kristen Harrington-Smith, Chief Commercial Officer; Mohamed Zaki, Chief Medical Officer; and Pepe Carmona, Chief Financial Officer, will discuss recent business highlights and review our third-quarter 2023 financial results before opening the call for questions.

Before we begin, I would like to remind listeners that some of the statements made during this

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.